| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $520,056 ) |
| | 2025 | 2025 | AMPLO BIOTECHNOLOGY INC | 2223 AVENIDA DE LA PLAYA STE 108 | LA JOLLA | CA | 92037-3217 | SAN DIEGO | USA | R42NS127713 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | 000 | 3 | NIH | 4/1/2025 | $520,056 |
| | 2025 | 2023 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 000 | 3 | NIH | 2/27/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $3,206,448 ) |
| | 2024 | 2024 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 000 | 4 | NIH | 9/13/2024 | $2,999,358 |
| | 2024 | 2024 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R42NS127713 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | 000 | 2 | NIH | 6/18/2024 | $207,090 |
|
| Issue Date FY: 2023 ( Subtotal = $637,213 ) |
| | 2023 | 2023 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R42NS127713 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | 000 | 1 | NIH | 5/26/2023 | $493,111 |
| | 2023 | 2023 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R42NS127713 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | 001 | 1 | NIH | 6/16/2023 | -$493,111 |
| | 2023 | 2023 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R42NS127713 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | 001 | 1 | NIH | 6/16/2023 | $493,111 |
| | 2023 | 2023 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 002 | 3 | NIH | 5/21/2023 | $144,102 |
| | 2023 | 2022 | AMPLO BIOTECHNOLOGY, INC. | 22 W PENNSYLVANIA AVE STE 310 | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 001 | 2 | NIH | 5/12/2023 | $0 |
| | 2023 | 2021 | AMPLO BIOTECHNOLOGY INC | 22 W PENNSYLVANIA AVE | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 000 | 1 | NIH | 10/12/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,458,731 ) |
| | 2022 | 2022 | AMPLO BIOTECHNOLOGY, INC. | 22 W PENNSYLVANIA AVE STE 310 | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 000 | 2 | NIH | 9/16/2022 | $1,458,731 |
|
| Issue Date FY: 2021 ( Subtotal = $253,925 ) |
| | 2021 | 2021 | AMPLO BIOTECHNOLOGY, INC. | 22 W PENNSYLVANIA AVE STE 310 | TOWSON | MD | 21204-5017 | BALTIMORE | USA | R44NS124351 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | 000 | 1 | NIH | 9/2/2021 | $253,925 |
|
|
